Hims & Hers Health, Inc. (BMV:HIMS)
Mexico · Delayed Price · Currency is MXN | Market Cap | 83.72B -41.8% |
| Revenue (ttm) | 42.26B +59.0% |
| Net Income | 2.31B +1.8% |
| EPS | 9.22 -3.7% |
| Shares Out | n/a |
| PE Ratio | 36.23 |
| Forward PE | 17.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500 |
| Average Volume | 2,752 |
| Open | 370.00 |
| Previous Close | 367.00 |
| Day's Range | 369.00 - 370.00 |
| 52-Week Range | 240.00 - 1,330.00 |
| Beta | 2.32 |
| RSI | 50.82 |
| Earnings Date | May 11, 2026 |
About Hims & Hers Health
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and de... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial numbers in USD Financial StatementsNews
Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2026 financial results...
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Heal...
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
Telehealth giant Hims & Hers says its customer support system was hacked
Hims & Hers, the telehealth company that sells weight-loss drugs and sexual health prescriptions, has confirmed a data breach affecting its third-party customer service platform.
Novo Nordisk's FDA-Approved GLP-1s Now Available With Hims & Hers
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisk's FDA-approved GLP-1 medications are available to eligible customers, incl...
OWL, HIMS, TSLA And More: 5 Stocks Investors Couldn't Stop Buzzing About This Week
Retail investors talked up five hot stocks this week (March 9 to March 13) on X and Reddit's r/WallStreetBets, driven by retail hype, earnings, AI buzz, and corporate news flow.
Hims & Hers Names Kathryn Beiser as Chief Communications Officer
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Office...
Introducing Hims & Hers Benefits, Unlocking Health & Wellness Discounts for Subscribers
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best inno...
Stock Of The Day: Will Hims & Hers Go Into Another Short Squeeze?
The stock is now susceptible to a short squeeze, which occurs when a highly shorted stock has a rapid and large move higher. When the squeeze ends, the stock can crash and end up right back where it w...
Hims & Hers stock: why today's gains are unlikely to be sustainable
Hims & Hers Health Inc (NYSE: HIMS) soared nearly 50% this morning after announcing a landmark settlement and partnership with the Danish pharma giant – Novo Nordisk (NYSE: NVO). This meteoric run era...
Hims & Hers stock price is surging today. A surprising deal with Novo Nordisk is the reason why
Shares in Hims & Hers Health (NYSE: HIMS) are soaring this morning after a report that the telehealth company is entering into a deal with Novo Nordisk A/S (NYSE: NVO) to sell its popular GLP-1 weight...
HIMS Skyrockets on Reported Deal with NVO to Sell GLP-1s
Multiple reports state that Hims & Hers (HIMS) will partner with Novo Nordisk (NVO) to sell its GLP-1s through the telehealth company's platform. Marley Kayden covers the twists and turns of this tale...
Novo Nordisk drops Him & Hers lawsuit
Novo Nordisk has dropped its patent lawsuit against Hims & Hers after the telehealth provider agreed to sell Novo's branded medicines. “We've decided to drop the court proceedings and don't expect to ...
Hims & Hers Stock Pops on a Deal With Rival Novo Nordisk—What You Need to Know
Hims & Hers Health stock is soaring to start the week.
Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal
Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digi...
Hims & Hers shares surge 50% after Novo Nordisk ends legal feud over compounded weight loss drugs
"We have decided to drop the current court proceedings," Novo CEO Mike Doustdar told CNBC on Monday, however, reserving the right to bring it back "if needed." It comes after an agreement between Novo...
What's Happening With HIMS Stock?
HIMS has risen 40% pre-market following reports of a settlement and collaboration with Novo Nordisk to market its branded weight-loss drug on the Hims platform.
Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic, drops lawsuit
Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' platform, the Danish drugmaker said on Monday, ending a legal dispute that erupte...
Hims & Hers Announces Strategic Shift for US Weight Loss Business
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced a collaboration with Novo Nordisk as part of a new strategy for weight loss care treatments involving GLP-1s, evol...
Hims & Hers, Novo Nordisk Weight-Loss Drug Deal Ends Legal Feud, Stock Soars
Novo Nordisk has decided to sell its weight-loss drug through Hims & Hers' telehealth platform, following a lawsuit over patent violations regarding a compounded version of semaglutide products.
Hims shares jump after report of Novo Nordisk partnership that may end legal feud
Hims & Hers' shares were up over 50% in premarket trading on Monday following reports Novo Nordisk plans to sell its weight-loss drugs on the telehealth firm's platform, signaling a potential end to...
Hims & Hers Stock Soars 54%. It's Struck a Truce With Novo Nordisk, Report Says.
Novo has agreed to sell its weight-loss drugs on Hims' platform, according to a report.
Hims & Hers Shares Double on Report of Wegovy Tie-Up
Stock skyrocketed premarket following a media report that the maker of Wegovy plans to sell the weight-loss drug on the platform.
Hims & Hers stock rockets on reported end to Novo Nordisk weight-loss drug dispute
Hims & Hers shares jumped nearly 50% in premarket trade on Monday after a report it has ended a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.
Novo and Hims resolve dispute, will sell obesity drugs together, Bloomberg News reports
Wegovy maker Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health platform, bringing an end to a dispute between the two companies that escalated into a legal battle last mon...